WO1991005258A1 - Rheumatoid factor activity encoded by variant immunoglobulin variable region - Google Patents
Rheumatoid factor activity encoded by variant immunoglobulin variable region Download PDFInfo
- Publication number
- WO1991005258A1 WO1991005258A1 PCT/US1990/005311 US9005311W WO9105258A1 WO 1991005258 A1 WO1991005258 A1 WO 1991005258A1 US 9005311 W US9005311 W US 9005311W WO 9105258 A1 WO9105258 A1 WO 9105258A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- chain
- mutations
- human light
- sequence
- composition according
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/10—Musculoskeletal or connective tissue disorders
- G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
- G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints
Definitions
- the technical field of the subject invention is the diagnosis and therapy of erosive arthritis.
- Erosive arthritis is a chronic destructive inflammatory joint disease, which includes rheumatoid arthritis as one type of the disease.
- Rheumatoid factors are antiglobulin antibodies that bind the Fc portion of IgG immunoglobulins and are implicated in the pathogenesis of rheumatoid arthritis.
- Rheumatoid factors in patients with efosive arthritis may be different from rheumatoid factor in individuals without rheumatoid arthritis, as indicated by studies of rheumatoid factor specificity and idiotype.
- the genetic and molecular basis for rheumatoid factor autoantibodies in patients with erosive arthritis is completely unknown.
- compositions in the immune system which lead to erosive arthritis could provide means for diagnosis and treatment of the disease.
- rheumatoid factors are antiglobulin antibodies that bond the Fc portion of IgG immunoglobulins and are implicated in the pathogenesis of rheumatoid arthritis. Allen and Kunkel, Arthritis Ragum. 9:758-768 (1966) and Fong et al., J. Immunol.
- compositions are provided for the diagnosis and treatment of rheumatoid arthritis, where peptides comprising mutants of conserved framework regions encoded by germline genes for antibody light chains are found to be diagnostic of rheumatoid factor.
- antibodies find use as therapeutics to inhibit the rheumatoid factor activity of the mutant light chain.
- Methods and compositions are provided for the diagnosis and treatment of erosive arthritis, which includes about 70% of patients with rheumatoid
- the light chain of immunoglobulin is mutated at a conserved site in the framework region, having at least one mutation, frequently having two or more mutations, usually not more than three mutations.
- the framework regions are the 1, 2 and 3 framework regions (FR-1, -2, and -3) where the mutations of interest are particularly in the FR-3 region and more particularly at sites 62 and 65.
- the light chains are divided into kappa and lambda, where the mutations are of particular interest in the kappa light chain, and where the kappa light chains are divided into subgroups I-IV, of particular interest is kappa II.
- conserved region is intended that at least about 80%, preferably at least about 85% and more preferably at least about 90% of known light chain sequences have the same amino acid or a conservative mutation at the particular site.
- conserved amino acids of the third framework region include the following sequence: G-V-P-R-F-S-S-G-S-T-F-T-L-I-R-V-V-G-V-Y-Y-C (57-88).
- phenylalanine occurs in all four of the kappa subgroups and is present in 78/80 of reported kappa light chains; only one light chain (a V I ) contains a change to valine while the other chain was a different amino acid.
- the mutation in the conserved region may be a conservative or non-conservative change, that is , it may be an exchange of one polar amino acid for another polar amino acid, or a nonpolar amino acid for a polar amino acid, an aliphatic amino acid for an aromatic amino acid, a charged polar amino acid for a non- charged polar amino acid, vice versa, or the like.
- a conservative or non-conservative change that is , it may be an exchange of one polar amino acid for another polar amino acid, or a nonpolar amino acid for a polar amino acid, an aliphatic amino acid for an aromatic amino acid, a charged polar amino acid for a non- charged polar amino acid, vice versa, or the like.
- the substitutions may be conservative or non-conservative, where the following table indicates conservative substitutions, where the same amino acids are found on the same line.
- the substitution may have the same charge or neutrality as the wild type amino acid.
- J chain associated with the mutation In addition, of interest will be the particular J chain associated with the mutation. Of particular interest is the presence of a J5 segment associated with the mutant light chain.
- the mutations will normally be associated with the germline gene, so that the variable region exon will include the mutation.
- Oligopeptides may be provided which are of at least eight amino acids, and, furthermore, encompass the mutant framework region.
- the oligopeptides will generally be fewer than about 60 amino acids, more usually fewer than about 36 amino acids, although large oligopeptides may be employed to inhibit binding of the mutant framework region to other antibodies.
- oligopeptides may be prepared synthetically which are specific for the binding site of the mutant antibody, so as to be able to bind to the mutant antibody and prevent its binding to an homologous ligand other than the
- synthesized peptide These peptides can be readily prepared in large number and screened for binding affinity to the particular antibody.
- the peptides may be used individually or in combination, blocking binding of the mutant antibody to other antibodies or proteins.
- the entire mutant light chain may be employed, but since this is not necessary, it will be frequently convenient to use a fragment of the light chain.
- the entire light chain may be used in purified form, generally greater than about 90%, usually greater than about 95% pure, in place of the oligopeptide.
- antibodies in a monovalent form such as Fab, Fab', or Fv or an antiidiotype, where the variable region of the antiidiotype may compete with the mutant framework region and the antiidiotype is monovalent.
- Fab fragment antigen binding domain
- Fab' fragment antigen binding domain
- a single variable region of the antiidiotype antibody may be employed to inhibit binding.
- a sequence of particular interest is an eight amino acid sequence coming within the sequence
- GVPDRVSGRGSGTDF where additional amino acids from the framework region of the kappa light chain particularly the kappa II light chain may be present, but the eight or greater amino acid sequence includes the sequence VSGR.
- oligo- or polypeptides may be modified in a variety of ways to enhance their stability, such as using an unnatural amino acid, such as the D- amino acid, at other than the tetrad indicated above, by functionalizing the amino or carboxy terminus, e.g., for the amino group, acylation or alkylation, and for the carboxy group, esterifi- cation or amidification, or the like.
- Other methods of stabilization may include liposome formation, other forms of encapsulation, etc.
- the presence of a mutant light chain may be detected in a variety of ways. For example, one may use PCR (polymerase chain reaction), using either the mutated or the natural sequence or both as primers to detect the presence of the mutation in germline DNA of a human host. Alternatively, one may use primers which are based on conserved regions which flank the mutated region of interest and sequence the resulting DNA to determine the presence of mutations. Alternatively, one may provide for antibodies specific for the mutated framework region, which can distinguish the mutated framework region from the wildtype framework region, and detect the presence of antibodies which bind to the antibody for the mutated framework region. If
- Immunoassays include ELISA, EMIT, CEDIA, SLIFA, and the like.
- a variety of patents have issued describing a number of diagnostic procedures, which include U.S. Patent Nos. 3,791,932; 3,817,837; 3,398,943, and references cited therein.
- the subject peptides may also be used for therapy, in inhibiting rheumatoid factor activity of the mutated framework region antibodies.
- compositions may be administered by any convenient way, preferably intravascularly or peritoneally, conveniently in a physiologically acceptable carrier, e.g., phosphate buffered saline, saline, deionized water, or the like.
- a physiologically acceptable carrier e.g., phosphate buffered saline, saline, deionized water, or the like.
- the amount administered will be in the range of about 100 to 1000 ⁇ g/kg of the
- a single bolus may be employed or repetitive administrations may be employed, generally not more frequently than once weekly.
- the concentration of the peptide will generally be in the range of about 100 to 500 yg/ml in the dose administered.
- Other additives may be included, such as stabilizers, bacteriocides, etc. These additives will be present in conventional amounts.
- the subject peptides may be prepared in a variety of ways. Peptides under about 60 amino acids can be readily synthesized today using conventional commercially available automatic synthesizers.
- DNA sequences may be prepared encoding the desired peptide and inserted into an appropriate expression vector for expression in a prokaryotic or eukaryotic host.
- a wide variety of expression vectors are available today and may be used in conventional ways for transformation of a competent host for expression and isolation.
- the open reading frame encoding the desired peptide may be joined to a signal sequence for secretion, so as to permit
- the IgG RF was detected by an enzyme- linked immunosorbent assay (ELISA) using purified human IgG Fc fragments bound to 96 well microtiter plates (Weisbart et al., J.
- Isotype testing with subclass specific antiglobulins identified only human IgG 4 subclass gamma heavy chains.
- immunoglobulin was demonstrated by its binding to purified Fc fragments of human IgG, but not human serum albumin, bovine collagen, histone 2A, or denatured DNA, as shown in the following table.
- the human monoclonal antibody hRF-1 was bound to 96-well microtiter plastic plates at 1 ⁇ g/100 ⁇ L and characterized by ELISA using peroxidase conjugated antisera specific for human immunoglobulin isotypes, IgG subclasses, and light chains.
- the antigenic specificity of hRF-1 monoclonal was measured with the 5 antigens bound to 96-well microtiter plates at 1 ⁇ g/100 ⁇ L by adding hRF-1 at 2 ⁇ g/ml from culture media and detecting bound hRF-1 with affinity purified peroxidase-conjugated sheep antibodies specific for F(ab') 2 of human IgG. Results were recorded as absorbancy at 414 nm corrected for background values using control ELISA wells coated only with poly-L-lysine.
- the hRF-1 human monoclonal IgG 4 RF was tested for binding to different species' IgGs and shown to bind to human, rabbit, mouse and guinea pig IgG more strongly than to horse, goat, and sheep IgG.
- the monoclonal IgG 4 RF did not bind at all to chicken
- HRF-1 lymphoblast cells were grown in serum free medium, and 2.0 mg of mAb hRF-1 was purified from 40 liters of serum free supernatant by absorption to 4 gm of Protein A Sepharose CL-4B (Pharmacia,
- MAb hRF-1 (1 mg/ml), (see U.S. application serial no. 562,781, filed March 30, 1987, whose disclosure is incorporated herein by reference), was reduced in a nitrogen environment using 2 mM dithioerythritol for 1 hr at room temperature, pH 8.3, and then alkylated with 22 mM iodoacetamide for 2 hr on ice.
- the column flow rate was 1.0 ml/min, and 0.5 ml fractions were collected.
- the protein fractions were identified spectrophotometrically (A 280 ).
- mAb hRF-1 and isolated light and heavy chains (20 ⁇ g/ml) were biotinylated in a molar ratio of 1:30 with NHS-LC-Biotin (Pierce Chemical Co., Rockford, IL) overnight at 4°C in N,N-dimethylformamide adjusted to pH 8.5 with 5% Na 2 CO 3 .
- Biotinylated peptides were dialyzed against PBS and assayed for binding human IgG and other mammalian IgG immunoglob- ulins by ELISA. Binding was measured by adding
- mAb Gm607 streptavidin conjugated with alkaline phosphatase, and bound phosphatase was measured by the conversion of p-nitrophenyl phosphate to p-nitrophenol (A 405 ).
- variable region of mAb hRF-1 light chain predicted from the nucleotide sequence
- the amino acid sequence is compared to Gm607, a prototype V ⁇ II light chain produced by a lymphoblast cell line derived from a normal individual (Klobeck et al., Nature 309:73-76 (1984).
- the Gm607 amino acid sequence was also predicted from the nucleotide sequence.
- Six other reported V ⁇ II light chains are shown for comparison.
- the amino acid sequence of hRF-1 is identical to Gm607 with the exception of two amino acid changes, corresponding to a change from phenyl- alanine to valine at residue 62 and a change from serine to arginine at residue 65. These amino acid changes occur in a relatively invariable region of FR3.
- the gene for the immunoglobulin light chain of hRF-1 cells was cloned from a cDNA library expressed in Lambda Zap (Stratagene, La Jolla, CA), and the cDNA library was screened with a V k J chain oligonucleotide probe labeled with 32 P.
- Lambda Zap-hRF-1 was converted to Bluescript, from which double stranded and single stranded DNA were isolated (Stratagene, La Jolla, CA), and dideoxy sequencing was performed using an Applied BioScience Sequenator.
- a 156 bp fragment is amplified in hRF-1 genomic DNA, hRF-1 cDNA, and normal PBL DNA.
- the 156 bp fragment amplified from DNA from -normal peripheral blood lymphocytes (PBL) did not contain a Tthllll site. In contrast, a Tthllll site was present in hRF-1 cDNA.
- a second Haelll site is present in hRF-1 cDNA which produces an additional fragment.
- a nucleotide sequence of 156 bp was amplified following 25 cycles of PCR with hRF-1 genomic DNA, cDNA prepared from hRF-1 polyadenylated mRNA by reverse transcriptase, and DNA isolated from normal PBL.
- Oligonucleotide primers (100 ng) were used flanking the sequences in question.
- the primers used for PCR were TCTCCACAGCTCCTGATCT (sense) located at amino acids 43-48 and TTGTAGAGCTTGCATGCA (antisense) located at amino acids 88-93 in the 5' to 3' orientation.
- the antisense primer was labeled with [ ⁇ 32 P]ATP. Reactions were performed in 25 mM tris-HCl, pH 8.0, 5 mM MgCl 2 , 50 mM NaCl, and 0.25 mM each of deoxyadenosine
- the autoradiograph was overexposed to enhance the Tthllll and Haelll fragments in genomic DNA where the V ⁇ II of interest is diluted by multiple other V kII genes compared to amplification of the single hRF-1 V ⁇ II in the hRF-1 cDNA.
- the autoradiograph showed the absence of bands in normal DNA from PBL uncut or cut with Haelll
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US41477689A | 1989-09-29 | 1989-09-29 | |
US414,776 | 1989-09-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1991005258A1 true WO1991005258A1 (en) | 1991-04-18 |
Family
ID=23642916
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1990/005311 WO1991005258A1 (en) | 1989-09-29 | 1990-09-18 | Rheumatoid factor activity encoded by variant immunoglobulin variable region |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP0494265A4 (en) |
JP (1) | JPH05500670A (en) |
CA (1) | CA2066674A1 (en) |
WO (1) | WO1991005258A1 (en) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4659678A (en) * | 1982-09-29 | 1987-04-21 | Serono Diagnostics Limited | Immunoassay of antigens |
US4863850A (en) * | 1984-09-14 | 1989-09-05 | Asahi Medical Co., Ltd | Method for diagnosis of rheumatoid arthritis |
-
1990
- 1990-09-18 JP JP2514951A patent/JPH05500670A/en active Pending
- 1990-09-18 CA CA002066674A patent/CA2066674A1/en not_active Abandoned
- 1990-09-18 EP EP19900915960 patent/EP0494265A4/en not_active Withdrawn
- 1990-09-18 WO PCT/US1990/005311 patent/WO1991005258A1/en not_active Application Discontinuation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4659678A (en) * | 1982-09-29 | 1987-04-21 | Serono Diagnostics Limited | Immunoassay of antigens |
US4863850A (en) * | 1984-09-14 | 1989-09-05 | Asahi Medical Co., Ltd | Method for diagnosis of rheumatoid arthritis |
Non-Patent Citations (1)
Title |
---|
See also references of EP0494265A4 * |
Also Published As
Publication number | Publication date |
---|---|
EP0494265A4 (en) | 1992-12-16 |
EP0494265A1 (en) | 1992-07-15 |
CA2066674A1 (en) | 1991-03-30 |
JPH05500670A (en) | 1993-02-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0263072B1 (en) | Novel lymphokine related peptides | |
Lieberman et al. | Genetics of a new IgVH (T15 idiotype) marker in the mouse regulating natural antibody to phosphorylcholine | |
AU2004220156B2 (en) | Monoclonal antibody and hybridoma producing the same | |
Bloom et al. | V region gene analysis of anti-Sm hybridomas from MRL/Mp-lpr/lpr mice. | |
US5512435A (en) | Receptor-binding antiproliferative peptides | |
Božič et al. | Sera from patients with rheumatic diseases recognize different epitope regions on the 52‐kD Ro/SS‐A protein | |
JPH0730116B2 (en) | Human interleukin-4 antibody antagonist | |
EP0364778B1 (en) | Antibody against interleukin-1beta | |
EP0491878B1 (en) | Compositions for the inhibition of protein hormone formation and uses thereof | |
Sioud et al. | Characterization of naturally occurring autoantibodies against tumour necrosis factor‐alpha (TNF‐α): in vitro function and precise epitope mapping by phage epitope library | |
Fett et al. | A monoclonal antibody to human angiogenin. Inhibition of ribonucleolytic and angiogenic activities and localization of the antigenic epitope | |
EP0499112A1 (en) | Antibodies against an IgE receptor | |
WO1993007485A1 (en) | Rare immunoglobulin framework regions associated with human disease | |
US4882424A (en) | Activation antigen | |
Jacob et al. | Altered cell-surface protein (s), crossreactive with DNA, on spleen cells of autoimmune lupic mice. | |
Watts et al. | A human fetal monoclonal DNA-binding antibody shares idiotypes with fetal and adult murine monoclonal DNA-binding antibodies. | |
Hefta et al. | Expression of carcinoembryonic antigen and its predicted immunoglobulin-like domains in HeLa cells for epitope analysis | |
Quinn et al. | Autoantibody germ-line gene segment encodes VH and VL regions of a human anti-streptococcal monoclonal antibody recognizing streptococcal M protein and human cardiac myosin epitopes. | |
EP0539975A1 (en) | Method for immunological assay of free lipoprotein-associated coagulation inhibitor (LACI) and kit therefor | |
WO1991005258A1 (en) | Rheumatoid factor activity encoded by variant immunoglobulin variable region | |
Bogen | Monoclonal antibodies specific for variable and constant domains of murine λ chains | |
Meek et al. | Anti-peptide antibodies detect a lupus-related interspecies idiotype that maps to H chain CDR2. | |
US6160107A (en) | Nucleic acids encoding antigens associated with polymyositis and dermatomositis | |
Kamatani et al. | Detection of an amino acid substitution in the mutant enzyme for a special type of adenine phosphoribosyltransferase (APRT) deficiency by sequence-specific protein cleavage. | |
Garcia-Lozano et al. | Presence of antibodies to different subunits of replication protein A in autoimmune sera. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): CA JP |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB IT LU NL SE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1990915960 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2066674 Country of ref document: CA |
|
WWP | Wipo information: published in national office |
Ref document number: 1990915960 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1990915960 Country of ref document: EP |